Literature DB >> 21288012

Enhanced binding of apolipoprotein A-I variants associated with hypertriglyceridemia to triglyceride-rich particles.

Irina N Gorshkova1, David Atkinson.   

Abstract

Hypertriglyceridemia (HTG) is a common lipid abnormality in humans. However, its etiology remains largely unknown. It was shown that severe HTG can be induced in mice by overexpression of wild-type (WT) apolipoprotein E (apoE) or specific apoA-I mutants. Certain mutations in apoE4 were found to affect plasma triglyceride (TG) levels in mice overexpressing the protein. HTG appeared to positively correlate with the ability of the apoE4 variants to bind to TG-rich particles, protein destabilization, and the exposure of protein hydrophobic surface in solution. Here, we propose that the apoA-I mutations that cause HTG may also lead to changes in the conformation and stability that promote binding of apoA-I to TG-rich lipoproteins. To test this hypothesis, we studied binding to TG-rich emulsion and biophysical properties of the apoA-I mutants that induce HTG, apoA-I[E110A/E111A] and apoA-I[Δ(61-78)], and compared them to those of WT apoA-I and another apoA-I mutant, apoA-I[Δ(89-99)], that does not induce HTG but causes hypercholesterolemia in mice. We found that the apoA-I[E110A/E111A] and apoA-I[Δ(61-78)] mutations lead to enhanced binding of apoA-I to TG-rich particles, destabilization, and greater exposure of the hydrophobic surface of the protein. The apoA-I[Δ(89-99)] mutant did not show enhanced binding to the emulsion or a more exposed hydrophobic surface. Thus, like apoE4, the apoA-I variants that cause HTG in mice have the altered conformation and stability that facilitate their binding to TG-rich lipoproteins and thereby may lead to the reduced level of lipolysis of these lipoproteins. While many factors may be involved in induction of HTG, we suggest that an increased level of association of destabilized loosely folded apolipoproteins with TG-rich lipoproteins may contribute to some cases of HTG in humans.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21288012      PMCID: PMC6128146          DOI: 10.1021/bi200158b

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  40 in total

Review 1.  The unique role of apolipoprotein A-I in HDL remodeling and metabolism.

Authors:  Henry J Pownall; Christian Ehnholm
Journal:  Curr Opin Lipidol       Date:  2006-06       Impact factor: 4.776

2.  Determination of the secondary structures of proteins by circular dichroism and optical rotatory dispersion.

Authors:  Y H Chen; J T Yang; H M Martinez
Journal:  Biochemistry       Date:  1972-10-24       Impact factor: 3.162

Review 3.  The effects of altered apolipoprotein A-I structure on plasma HDL concentration.

Authors:  Mary G Sorci-Thomas; Michael J Thomas
Journal:  Trends Cardiovasc Med       Date:  2002-04       Impact factor: 6.677

4.  Role of buried polar residues in helix bundle stability and lipid binding of apolipophorin III: destabilization by threonine 31.

Authors:  Paul M M Weers; Wazir E Abdullahi; Jamie M Cabrera; Tzu-Chi Hsu
Journal:  Biochemistry       Date:  2005-06-21       Impact factor: 3.162

5.  Study of the "molten globule" intermediate state in protein folding by a hydrophobic fluorescent probe.

Authors:  G V Semisotnov; N A Rodionova; O I Razgulyaev; V N Uversky; A F Gripas'; R I Gilmanshin
Journal:  Biopolymers       Date:  1991-01       Impact factor: 2.505

6.  Generation of a recombinant apolipoprotein E variant with improved biological functions: hydrophobic residues (LEU-261, TRP-264, PHE-265, LEU-268, VAL-269) of apoE can account for the apoE-induced hypertriglyceridemia.

Authors:  Kyriakos E Kypreos; Ko W van Dijk; Louis M Havekes; Vassilis I Zannis
Journal:  J Biol Chem       Date:  2004-12-02       Impact factor: 5.157

7.  Deletions of helices 2 and 3 of human apoA-I are associated with severe dyslipidemia following adenovirus-mediated gene transfer in apoA-I-deficient mice.

Authors:  Angeliki Chroni; Horng-Yuan Kan; Adelina Shkodrani; Tong Liu; Vassilis I Zannis
Journal:  Biochemistry       Date:  2005-03-15       Impact factor: 3.162

8.  Lipid-free structure and stability of apolipoprotein A-I: probing the central region by mutation.

Authors:  Irina N Gorshkova; Tong Liu; Vassilis I Zannis; David Atkinson
Journal:  Biochemistry       Date:  2002-08-20       Impact factor: 3.162

9.  Influence of tertiary structure domain properties on the functionality of apolipoprotein A-I.

Authors:  Masafumi Tanaka; Mao Koyama; Padmaja Dhanasekaran; David Nguyen; Margaret Nickel; Sissel Lund-Katz; Hiroyuki Saito; Michael C Phillips
Journal:  Biochemistry       Date:  2008-01-19       Impact factor: 3.162

10.  Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies.

Authors:  J E Hokanson; M A Austin
Journal:  J Cardiovasc Risk       Date:  1996-04
View more
  4 in total

1.  Increased Binding of Apolipoproteins A-I and E4 to Triglyceride-Rich Lipoproteins is linked to Induction of Hypertriglyceridemia.

Authors:  Irina N Gorshkova; David Atkinson
Journal:  JSM Atheroscler       Date:  2017-02-13

2.  Alteration of negatively charged residues in the 89 to 99 domain of apoA-I affects lipid homeostasis and maturation of HDL.

Authors:  Andreas K Kateifides; Irina N Gorshkova; Adelina Duka; Angeliki Chroni; Dimitris Kardassis; Vassilis I Zannis
Journal:  J Lipid Res       Date:  2011-04-19       Impact factor: 5.922

3.  Binding of human apoA-I[K107del] variant to TG-rich particles: implications for mechanisms underlying hypertriglyceridemia.

Authors:  Irina N Gorshkova; Xiaohu Mei; David Atkinson
Journal:  J Lipid Res       Date:  2014-06-11       Impact factor: 5.922

4.  Amyloidogenic mutations in human apolipoprotein A-I are not necessarily destabilizing - a common mechanism of apolipoprotein A-I misfolding in familial amyloidosis and atherosclerosis.

Authors:  Madhurima Das; Xiaohu Mei; Shobini Jayaraman; David Atkinson; Olga Gursky
Journal:  FEBS J       Date:  2014-04-28       Impact factor: 5.542

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.